The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma. Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: The median first-line PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p = 0.0014); 14, 7, and 2 months (p=0.0002); and 41, 21, and 8 months (p<0.0001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.0047); 10, 7, and 3 months (p=0.0023); and 50, 21, and 8 months (p<0.0001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.
Cancer research and treatment : official journal of Korean Cancer Association. 2018 Sep 07 [Epub ahead of print]
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung, Korean Renal Cell Carcinoma Study Group
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea., Department of Urology, Center for Prostate Cancer, National Cancer Center, Goyang, Korea., Biometric Research Branch, Center for Prostate Cancer, National Cancer Center, Goyang, Korea., Department of Urology, Sungkyunkwan University College of Medicine, Seoul, Korea., Department of Urology, Seoul National University College of Medicine, Seoul, Korea., Department of Urology, University of Ulsan College of Medicine, Seoul, Korea., Department of Urology, Medical School, Chonnam National University, Hwasun, Korea., Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, Korea., Department of Urology, Seoul St. Mary's Hospital, The Catholic University, Seoul, Korea., Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.